Πλοήγηση ανά Συγγραφέα "Karanikas, V."
-
Anti-survivin antibody responses in lung cancer
Karanikas, V.; Khalil, S.; Kerenidi, T.; Gourgoulianis, K. I.; Germenis, A. E. (2009)Existing evidence regarding spontaneous anti-survivin humoral responses in lung cancer is inconclusive. Moreover, despite that cancer cell death elicited by radiotherapy and some chemotherapeutic agents seems to be ... -
Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals
Karanikas, V.; Soukou, F.; Kalala, F.; Kerenidi, T.; Grammoustianou, E. S.; Gourgoulianis, K. I.; Germenis, A. E. (2008)Survivin and its variant survivin-2B have been considered as potential candidates for cancer immunotherapy. The magnitude however of spontaneously occurring CD8+ T cells circulating precursor CTLs (pCTL), has never been ... -
Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy
Karanikas, V.; Tsochas, S.; Boukas, K.; Kerenidi, T.; Nakou, M.; Dahabreh, J.; Poularakis, T.; Gourgoulianis, K.; Germenis, A. (2008) -
Cord blood as a source of non-senescent lymphocytes for tumor immunotherapy
Germenis, A. E.; Karanikas, V. (2010)While proof of concept that the immune system can be harnessed to attack cancer cells has been established, only a minority of patients are cured with immunotherapeutic regimens designed to enhance host autologous immunity. ... -
Cord blood lymphocytes combating immunosenescence
Germenis, A. E.; Karanikas, V. (2009) -
Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects
Karanikas, V.; Zamanakou, M.; Soukou, F.; Kerenidi, T.; Tsougos, I.; Theodorou, K.; Georgoulias, P.; Gourgoulianis, K. I.; Germenis, A. E. (2010)Background: This study aimed to examine whether EBV seropositive patients with lung cancer have an altered virus-specific CTL response, as compared to age-matched healthy controls and whether any variation in this response ... -
Determinants of cancer immunotherapy success
Karanikas, V.; Germenis, A. (2010) -
Foxp3 expression in human cancer cells
Karanikas, V.; Speletas, M.; Zamanakou, M.; Kalala, F.; Loules, G.; Kerenidi, T.; Barda, A. K.; Gourgoulianis, K. I.; Germenis, A. E. (2008)Objective: Transcription factor forkhead box protein 3 (Foxp3) specifically characterizes the thymically derived naturally occurring regulatory T cells (Tregs). Limited evidence indicates that it is also expressed, albeit ... -
Foxp3 Expression in Liver Correlates with the Degree but Not the Cause of Inflammation
Speletas, M.; Argentou, N.; Germanidis, G.; Vasiliadis, T.; Mantzoukis, K.; Patsiaoura, K.; Nikolaidis, P.; Karanikas, V.; Ritis, K.; Germenis, A. E. (2011)Patients with chronic viral hepatitis display increased expression of Foxp3 in liver, suggesting that Tregs expansion contributes to persistent infection. The purpose of this study was to elucidate whether the expression ... -
Immunoepigenetics: the unseen side of cancer immunoediting
Germenis, A. E.; Karanikas, V. (2007)Cancer immunosurveillance representing, till recently, the explanatory framework relating cancer and the immune system, does not convincingly explain tumor escape. At the beginning of the decade, a new theory emerged, ... -
Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer
Karanikas, V.; Zamanakou, M.; Kerenidi, T.; Dahabreh, J.; Hevas, A.; Nakou, M.; Gourgoulianis, K. I.; Germenis, A. E. (2007)Background: The expression of indoleamine 2,3-dioxygenase (IDO) by tumor cells has been considered as a major tumor immune escape mechanism. The aim of this study was to investigate the expression of IDO in lung cancer ... -
Indoleamine 2,3-dioxygenose (IDO) expression in lung cancer
Karanikas, V.; Zamanakou, M.; Kerenid, T.; Dahabreh, J.; Hevas, A.; Nakou, M.; Gourgoulianis, K. I.; Germenis, A. E. (2007)Background: The expression of indoleamine 2,3-dioxygenase (IDO) by tumor cells has been considered as a major tumor immune escape mechanism. The aim of this study was to investigate the expression of IDO in lung cancer ... -
Low-frequency cd8+T cell precursors specific for survivin and survivin-2b in cancer patients: A caveat for immunotherapy?
Karanikas, V.; Soukou, F.; Kalala, F.; Kerenidi, T.; Gourgoulianis, K.; Germenis, A. (2008) -
Naturally occurring tumor-specific CD8(+) T-cell precursors in individuals with and without cancer
Karanikas, V.; Zamanakou, M.; Soukou, F.; Kerenidi, T.; Gourgoulianis, K. I.; Germenis, A. E. (2010)Boosting pre-existing, naturally occurring cytolytic CD8(+) T-cell (CTLs) responses directed against class-I MHC-restricted peptides of tumor antigens, represents a primary goal of cancer immunotherapy. The number of ... -
Quantitative and qualitative assessment of anti-tumour specific T cells in patients with lung cancer and cancer free individuals
Karanikas, V.; Soukou, F.; Zamanakou, M.; Kalala, F.; Grammoustianou, E.; Kerenidi, T.; Gourgoulianis, K.; Germenis, A. (2008) -
Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses
Speletas, M.; Argentou, N.; Karanikas, V.; Gramoustianou, E. S.; Mandala, E.; Braimi, M.; Matsouka, P.; Ritis, K.; Germenis, A. E. (2011)Tyrosine-kinase inhibitors are very effective in patients with CML, but in most cases the disease relapses after their discontinuation. As a result, novel approaches should be considered, such as anti-survivin treatment ... -
Tumor immune escape mediated by indoleamine 2,3-dioxygenase
Zamanakou, M.; Germenis, A. E.; Karanikas, V. (2007)Amongst the numerous mediators contributing towards the escape Of tumors from the host's immune response against them, the enzyme indoleamine 2,3-dioxygenase (lDO) has recently attracted special attention. By catabolizing ... -
Tumor specific CD8(+) T cells in patients with lung cancer and healthy individuals
Karanikas, V.; Germenis, A. (2009)Lung cancer, one of the leading causes of cancer death in the developed world, presents with a poor 5-year survival, despite improvements in conventional treatments such as surgery, radiotherapy and chemotherapy. Lung ...